Shares of generic drug companies are slipping on Monday after Morgan Stanley analyst David Risinger downgraded Endo International (ENDP) and Teva Pharmaceutical (TEVA) to Underweight, a sell-equivalent rating, as he anticipates generic company pricing pressure, increasing competition and litigation risk downside. The analyst is… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id2933014/-Teva-Endo-under-pressure-as-analyst-says-sell-on-competition-opioid-risk)
next post